Trevi Therapeutics Stock Market Value
| TRVI Stock | USD 2.88 0.06 2.13% |
| Symbol | Trevi |
Trevi Therapeutics Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Trevi Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Trevi Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Trevi Therapeutics.
| 11/01/2024 |
| 12/01/2024 |
If you would invest 0.00 in Trevi Therapeutics on November 1, 2024 and sell it all today you would earn a total of 0.00 from holding Trevi Therapeutics or generate 0.0% return on investment in Trevi Therapeutics over 30 days. Trevi Therapeutics is related to or competes with Cue Biopharma, AN2 Therapeutics, Bioatla, Spero Therapeutics, Bolt Biotherapeutics, Coherus BioSciences, and Foghorn Therapeutics. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization o... More
Trevi Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Trevi Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Trevi Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.04 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 17.04 | |||
| Value At Risk | (6.01) | |||
| Potential Upside | 6.59 |
Trevi Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trevi Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Trevi Therapeutics' standard deviation. In reality, there are many statistical measures that can use Trevi Therapeutics historical prices to predict the future Trevi Therapeutics' volatility.| Risk Adjusted Performance | 0.0156 | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.63) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0166 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Trevi Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trevi Therapeutics Backtested Returns
Trevi Therapeutics is relatively risky at the moment. Trevi Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0056, which indicates the firm had a 0.0056% return per unit of risk over the last 3 months. We have found thirty technical indicators for Trevi Therapeutics, which you can use to evaluate the volatility of the company. Please validate Trevi Therapeutics' Coefficient Of Variation of 10102.12, risk adjusted performance of 0.0156, and Semi Deviation of 3.66 to confirm if the risk estimate we provide is consistent with the expected return of 0.0209%. The entity has a beta of 1.74, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Trevi Therapeutics will likely underperform. Trevi Therapeutics right now has a risk of 3.75%. Please validate Trevi Therapeutics potential upside, and the relationship between the total risk alpha and kurtosis , to decide if Trevi Therapeutics will be following its existing price patterns.
Auto-correlation | -0.39 |
Poor reverse predictability
Trevi Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Trevi Therapeutics time series from 1st of November 2024 to 16th of November 2024 and 16th of November 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Trevi Therapeutics price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Trevi Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Trevi Therapeutics lagged returns against current returns
Autocorrelation, which is Trevi Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Trevi Therapeutics' stock expected returns. We can calculate the autocorrelation of Trevi Therapeutics returns to help us make a trade decision. For example, suppose you find that Trevi Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Trevi Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Trevi Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Trevi Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Trevi Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Trevi Therapeutics Lagged Returns
When evaluating Trevi Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Trevi Therapeutics stock have on its future price. Trevi Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Trevi Therapeutics autocorrelation shows the relationship between Trevi Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Trevi Therapeutics.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out Trevi Therapeutics Correlation, Trevi Therapeutics Volatility and Trevi Therapeutics Alpha and Beta module to complement your research on Trevi Therapeutics. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Trevi Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.